/

Società

H.

Non verificato

H. Lundbeck A/S

Di cosa scriviamo

BiologiaEconomiaFarmaceuticaSanitàStart-up

7 comunicati stampa

Guarda tutti i comunicati

08/05/2025

Farmaceutica

Sanità

Lundbeck to share pipeline data and key insights into the progression of rare disease, Multiple System Atrophy, at International MSA Congress in Boston

Fonte

H. Lundbeck A/S

Emittente

1.00

0

06/05/2025

Farmaceutica

Information Technology

Telecomunicazioni

Sanità

Economia

Brevetti, marchi e copyright

Lundbeck joins forces with Danish Centre for AI Innovation to improve brain health by advancing drug discovery with Gefion AI supercomputer

Fonte

H. Lundbeck A/S

Emittente

1.00

0

04/04/2025

Farmaceutica

Sanità

Finanza

Biologia

Lundbeck to present positive pipeline data at American Academy of Neurology (AAN) Annual Meeting

Fonte

H. Lundbeck A/S

Emittente

1.00

0

31/03/2025

Farmaceutica

Sanità

Following a planned interim analysis in the PROCEED trial Lundbeck expands the dose finding to intravenous administration of Lu AG09222 in migraine prevention

Fonte

H. Lundbeck A/S

Emittente

1.00

0

26/03/2025

Farmaceutica

Sanità

Economia

Management

Organizzazione Aziendale

Lundbeck held its Annual General Meeting on 26 March 2025 at the company's registered office

Fonte

H. Lundbeck A/S

Emittente

1.00

0

13/03/2025

Farmaceutica

Sanità

Economia

Start-up

Biologia

Rxulti® (brexpiprazole) approved in the European Union for the treatment of schizophrenia in adolescents aged 13 years and older

Fonte

H. Lundbeck A/S

Emittente

1.00

0

10/03/2025

Farmaceutica

Sanità

Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan

Fonte

H. Lundbeck A/S

Emittente

1.00

0

Seguaci

0

Compatibilità

0